Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Ascendis Pharma ADR (NQ: ASND )

118.29 USD +0.78 (+0.66%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 19, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Ascendis Pharma ADR

Ascendis Pharma A/S Announces Presentations for TransCon™ PTH and TransCon™ CNP at the American Society for Bone & Mineral Research 2021 Annual Meeting
From GlobeNewswire News Releases
Ascendis Pharma A/S Announces Share Repurchase Program
From GlobeNewswire News Releases
Ascendis Pharma A/S Announces Mean Bone Mineral Density (BMD) Data from Phase 2 PaTH Forward Trial Demonstrating Continued Normalization and Stabilization of BMD Z-scores Between 26 and 58 Weeks
From GlobeNewswire News Releases
Ascendis Pharma A/S Announces Upcoming Investor Presentations
From GlobeNewswire News Releases
Ascendis Pharma A/S Submits Investigational New Drug Application to Initiate TransCon™ IL-2 β/γ Clinical Program
From GlobeNewswire News Releases
Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs
From GlobeNewswire News Releases
Ascendis Pharma A/S Announces Proposed Public Offering of ADSs
From GlobeNewswire News Releases
Ascendis Pharma A/S Reports Second Quarter 2021 Financial Results
From GlobeNewswire News Releases
Ascendis Pharma A/S Announces U.S. Food and Drug Administration Approval of SKYTROFA® (lonapegsomatropin-tcgd), the First Once-weekly Treatment for Pediatric Growth Hormone Deficiency
From GlobeNewswire News Releases
Ascendis Pharma A/S Announces Second Quarter 2021 Financial Results and Business Update Conference Call on August 25
From GlobeNewswire News Releases
Ascendis Pharma A/S Announces Upcoming Investor Presentations in August
From GlobeNewswire News Releases
Ascendis Pharma A/S Announces Target Enrollment Achieved in the Phase 3 PaTHway Trial of TransCon™ PTH (palopegteriparatide) in Adults with Hypoparathyroidism (HP) and Provides a Comprehensive Global
From GlobeNewswire News Releases
Ascendis Pharma A/S Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ hGH (Lonapegsomatropin) for Pediatric Growth Hormone Deficiency
Prescription Drug User Fee Act (PDUFA) goal date extended by three months for further review of submission to September 25, 2021 
From GlobeNewswire News Releases
Ascendis Pharma A/S Invites the Public to Attend “A Story of Courage: Living with Hypoparathyroidism” in Support of World Hypopara Awareness Day on June 1, 2021
Online event to include a live reading by Children’s Author, Ariana Feiner, whose short film documentary, A Story of Courage, has won 24 international awards 
From GlobeNewswire News Releases
Ascendis Pharma A/S Reports First Quarter 2021 Financial Results
From GlobeNewswire News Releases
Ascendis Pharma A/S Announces First Quarter 2021 Financial Results and Business Update Conference Call on May 27
From GlobeNewswire News Releases
Ascendis Pharma A/S Announces Expansion of Global Clinical Reach for TransCon™ PTH with Filing of the Clinical Trial Notification for Phase 3 Clinical Trial in Adults with Hypoparathyroidism in Japan
– Marks next step to bring the potential first ever hormone replacement therapy for hypoparathyroidism to Japan – 
From GlobeNewswire News Releases
Ascendis Pharma A/S Announces Preliminary 58-Week Results from Open-Label Extension of Phase 2 PaTH Forward Trial of TransCon PTH in Adult Hypoparathyroidism Demonstrated Durable Benefit and a Well-To
From GlobeNewswire News Releases
Ascendis Pharma A/S Announces Presentations for TransCon™ PTH at Upcoming Medical Conferences
From GlobeNewswire News Releases
Ascendis Pharma A/S Announces Participation at the BofA Securities 2021 Virtual Health Care Conference
From GlobeNewswire News Releases
Ascendis Pharma A/S Announces Presentations for TransCon™ hGH at Upcoming Medical Conferences
From GlobeNewswire News Releases
Ascendis Pharma A/S Announces Participation at the J.P. Morgan 10th Annual Napa Valley Biotech Forum
From GlobeNewswire News Releases
Ascendis Pharma A/S Presents 6-Month Open-Label Extension Data from Phase 2 PaTH Forward Trial of TransCon PTH in Adult Hypoparathyroidism at ENDO 2021
Clinical data demonstrate the potential of TransCon PTH as a hormone replacement therapy for adults with hypoparathyroidism 
From GlobeNewswire News Releases
Ascendis Pharma A/S Announces Participation at Oppenheimer 31st Annual Healthcare Conference
From GlobeNewswire News Releases
Ascendis Pharma A/S Reports Full Year 2020 Financial Results
From GlobeNewswire News Releases
Ascendis Pharma A/S Announces Seven Presentations at ENDO 2021, Demonstrating Commitment to People with Rare Endocrine Diseases
From GlobeNewswire News Releases
Ascendis Pharma A/S Announces Full Year 2020 Financial Results and Business Update Conference Call on March 10
From GlobeNewswire News Releases
Ascendis Pharma A/S Announces New “Outgrow GHD” Educational Resource to Support Rare Disease Day 2021
From GlobeNewswire News Releases
Ascendis Pharma A/S Announces Participation at SVB Leerink 10th Annual Global Healthcare Conference
From GlobeNewswire News Releases
Frazier Healthcare Partners Adds Highly Experienced Investor to Life Sciences Team
Frazier Healthcare Partners announced the planned addition of Albert Cha, M.D., Ph.D. as Managing Partner on the Life Sciences team. He has over 20 years of experience investing in public and private... 
From Business Wire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.